ImmunoCellular Therapeutics’ ICT-107 featured on CNN’s Sanjay Gupta MD

ImmunoCellular Therapeutics’ ICT-107 featured on CNN’s Sanjay Gupta MD

<0> For ImmunoCellular Therapeutics, Ltd.CEOcast, Inc.James Young, 212-732-4300Investor Relations </0>

ImmunoCellular Therapeutics (NYSE MKT: IMUC) a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it was featured on CNN’s Sanjay Gupta MD last weekend. The show profiled IMUC’s dendritic cell-based vaccine, ICT-07, which is currently undergoing a Phase IIb clinical trial treating newly diagnosed patients with glioblastoma multiforme, an aggressive, terminal form of brain cancer.

Dr. Sanjay Gupta is the multiple Emmy®-award winning chief medical correspondent for CNN. Gupta, a practicing neurosurgeon, plays an integral role in CNN’s reporting on health and medical news for Starting Point with Soledad O'Brien, Anderson Cooper 360°, CNN documentaries, and anchors the weekend medical affairs program Sanjay Gupta MD. Gupta also contributes to CNN.com and CNNHealth.com.

ImmunoCellular’s Phase IIb trial of ICT-107 is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107. The study is enrolling patients at medical institutions in collaboration with leading experts and opinion leaders in neuro-oncology.

A transcript of the CNN show can be found at:

ImmunoCellular Therapeutics () is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a Phase IIb trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit .

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.